CompletedPhase 1NCT00070538

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Studying Acute myeloid leukemia with 11q23 abnormalities

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vion Pharmaceuticals
Principal Investigator
Mario Sznol, MD
Vion Pharmaceuticals
Intervention
cytarabine(drug)
Eligibility
18 years · All sexes
Timeline
20032008

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00070538 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with 11q23 abnormalities

← Back to all trials